{
  "PTIX": {
    "city": "New York",
    "country": "United States",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Networking & Communication Devices",
    "long_name": "Protagenic Therapeutics, Inc.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Technology",
    "short_name": "Protagenic Therapeutics, Inc.",
    "state": "NY",
    "summary": "Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.",
    "website": "http://www.protagenic.com",
    "zipcode": "10010"
  }
}
